Clinical Research Directory
Browse clinical research sites, groups, and studies.
RT-310 Dose Escalation BPH Study
Sponsor: Resurge Therapeutics Inc.
Summary
RT-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.
Official title: Safety and Feasibility Dose Escalation Study for Evaluation of RT-310 for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Key Details
Gender
MALE
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-04-19
Completion Date
2027-12
Last Updated
2025-11-28
Healthy Volunteers
No
Interventions
RT-310
Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
Locations (4)
Australian Clinical Trials
Wahroonga, New South Wales, Australia
Goldfields Urology
Bendigo, Victoria, Australia
Western Urology
Maribyrnong, Victoria, Australia
Tauranga Urology Research
Tauranga, North Island, New Zealand